Patents for A61P 35 - Antineoplastic agents (221,099)
09/2008
09/24/2008CN101270362A Novel serine protease genes related to DPPIV
09/24/2008CN101270358A MiRNA sequence and uses thereof
09/24/2008CN101270354A Expression and application of B7-H4 in lung cancer cell
09/24/2008CN101270168A Hyaluronic acid stem grafting polyethylene imine copolymer, preparing method and application as genophore
09/24/2008CN101270163A Single-chain fragment antibody-polypeptide amalgamation protein and uses thereof
09/24/2008CN101270159A Antineoplastic cytotoxin of snake venom and preparing technique thereof
09/24/2008CN101270158A Target glioma resistant protein, preparation method and application
09/24/2008CN101270157A Genetic engineering target glioma Acp-W1 resistant protein, preparation method and application
09/24/2008CN101270154A Cyclo-pentapeptide with antineoplastic activity
09/24/2008CN101270145A Preparation technique for GHGKHKNK octapeptide and medicine use
09/24/2008CN101270144A Saponin for inhibiting liveness of tumor necrosis factor alpha, preparing method and medicine uses
09/24/2008CN101270143A Triterpene saponin antineoplastic compound, preparing method and uses
09/24/2008CN101270123A 20(S)-camptothecinum and method for preparing analogue
09/24/2008CN101270122A Amino acid norcantharidin acid imide derivative with optical activity and preparation method thereof
09/24/2008CN101270120A Novel tricyclic derivatives, method for preparing same and pharmaceutical compositions containing same
09/24/2008CN101270118A Technique for spherosinin purification with continuous column chromatography
09/24/2008CN101270102A Process for synthesizing parthenolide derivative and uses thereof
09/24/2008CN101270078A Metallic supermolecule compound for inhibiting telomere enzymatic activity, using method and uses thereof
09/24/2008CN101270069A Synthesis of taxol enhancers
09/24/2008CN101270060A 2,6-(amino-benzene methylene)naphthenone compounds, preparation method and application thereof
09/24/2008CN101269223A Anthracene nucleus medicament nano-preparation, preparation method and application thereof
09/24/2008CN101269214A Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
09/24/2008CN101269206A Chinese medicinal composition for treating testis cancer and preparation method thereof
09/24/2008CN101269198A Pure Chinese medicine preparation for preventing and treating enteron disease and improving self phylactic power, and preparation method thereof
09/24/2008CN101269187A Medicament composition for treating bladder cancer and preparation method thereof
09/24/2008CN101269159A Chinese medicinal composition for treating upper sinus frontalis cancer and preparation method thereof
09/24/2008CN101269134A Medicament for treating leukocythemia
09/24/2008CN101269113A Quality control method for medicament composition for treating knubble
09/24/2008CN101269110A Radix astragali fermentation liquor for inhibiting cancer cell growth and fermentation method
09/24/2008CN101269100A Application of goldenrod in preparing medicament for treating and preventing cancer
09/24/2008CN101269098A Sanqi fermentation liquor with effect of inhibiting cancer cell and preparation method thereof
09/24/2008CN101269092A Snake venom cytotoxin, preparation method and application thereof
09/24/2008CN101269087A Pectin-5-efudix colon cancer double-target ahead body medicament and preparation method
09/24/2008CN101269076A Medicine use of beta-methoxy acrylic ester compounds as novel STAT3 restrainer
09/24/2008CN101269065A Resveratrol and parthenolide compound for preventing and treating knubble disease
09/24/2008CN101269063A Application of epigallocatechin gallate in preparing product for preventing and treating human mammary cancer disease
09/24/2008CN101269050A Acidum citricum nolvadex capsule and preparation method thereof
09/24/2008CN101269012A Supersaturation self-microemulsion oral preparation of paclitaxel and its derivative
09/24/2008CN101269009A Novel anticancer injection
09/24/2008CN101269008A Novel anticancer sustained-release agent
09/24/2008CN101269007A Dosage form containing levorotation gossypol as active component
09/24/2008CN100420754C Method for preparing anthracene Ensamu bacterial
09/24/2008CN100420742C Oncolytic adenovirus with target for liver cancer and its preparation method and use
09/24/2008CN100420688C Pyrimido[4,5-d]pyrimidine derivatives with anticancer activity
09/24/2008CN100420687C Pyridino [2, 3-D] pyrimidine derivatives as selective KDR and FGFR inhibitors
09/24/2008CN100420680C Extraction and separation method of moleplant seed sterol
09/24/2008CN100420679C Novel compound, bacteria strain and method for producing novel compound using the strain
09/24/2008CN100420482C Method for short-term and long-term drug dosimetry
09/24/2008CN100420461C Pure natural antineoplastic medicine and preparation thereof
09/24/2008CN100420445C Fatty cream composition for maligant splanchnocoele hydrops and its preparing method
09/24/2008CN100420442C Pharmaceutical composition of scutellarin and baicalin with synergistic tumor resistance function
09/23/2008US7427681 Anticancer agents; antidiabetic agents; Alzheimer's disease
09/23/2008US7427660 Tumor antigen
09/23/2008US7427657 Aromatic sulfenates for type 1 phototherapy
09/23/2008US7427638 Treatment may include administration of a second active agent, including but not limited to, an anti-inflammatory agent, an immnunosuppressant, mycophenolate mofetil, a biologic agent, or a Cox-2 inhibitor
09/23/2008US7427631 especially as inhibitors of MMP12
09/23/2008US7427627 N-(4-(4-methylthiazol-5-yl) pyrimidin-2-yl)-N-phenylamines as antiproliferative compounds
09/23/2008US7427626 useful in Pharmaceutical medicines or pharmacological tools; cytostatic agents; antiproliferative/antineoplastic agents; 2-Anilino-4-[1-isopropyl-2-(hydroxyiminomethyl)imidazol-5-yl]pyrimidine; rheumatoid arthritis; breast cancer
09/23/2008US7427623 4-Amino-2,3-disubstituted thieno[2,3-d]pyrimidines and pharmacetical compositions thereof
09/23/2008US7427619 Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy
09/23/2008US7427616 e.g. 8-(1-methyl-4-phenyl-1H-imidazol-5-yl)-9H-purin-6-amine9-methyl-8-(1-methyl-4-phenyl-1H-imidazol-5-yl)-9H-purin-6-amine; Tie2 receptor tyrosine kinase and angiogenesis inhibitor; diabetic retinopathy, psoriasis, cancer, rheumatoid arthritis, atheroma, Kaposi's sarcoma and haemangioma
09/23/2008US7427615 3-substituted-4-pyrimidone derivatives
09/23/2008US7427610 e.g. 17 beta -Difluoromethyl-2-methoxy-estra-1,3,5(10)-trien-3-yl sulfamate; tubulin polymerization inhibitor; breast, prostate, colon, non-small-cell-lung cancer and primary dermal microvascular endothelial cell proliferation
09/23/2008US7427608 Protection against and treatment of hearing loss
09/23/2008US7427598 Post-natal administration of activity-dependent neurotrophic factor-derived polypeptides for enhancing learning and memory
09/23/2008US7427596 Having mutations in the Kinase domain region (KDR) and/or the FMS-like Tyrosine-Kinase region (FLT-1), said variants exhibiting modified binding characteristics at said regions compared with native VEGF; stimulates vasculogenesis or angiogenesis; wound healing
09/23/2008US7427592 Conjugate comprising polypeptide with N-glycosylation site and sugar; increase blood clot formation for treatment of thrombocytopenia and hemophilia
09/23/2008US7427495 Enhancing or inhibiting apoptosis
09/23/2008US7427418 Phloridzin-rich phenolic fraction and use thereof as a cosmetic, dietary or nutraceutical agent
09/23/2008US7427395 a Sendai virus envelope vector incorporated with anticancer or antitumor agents
09/23/2008CA2480800C Inhibitors of akt activity
09/23/2008CA2437820C Endomural therapy
09/23/2008CA2432872C Pyrazole compounds useful as protein kinase inhibitors
09/23/2008CA2418313C Piperidine derivatives and agent comprising the derivative as active ingredient
09/23/2008CA2378382C Carboxylic acid amides, pharmaceutical compositions containing these compounds, the use and preparation thereof
09/23/2008CA2372992C Selenium-containing pro-drugs for cancer therapy
09/23/2008CA2371393C Use of bismuth subgallate in inhibition of production of nitric oxide synthase
09/23/2008CA2354852C 4,5-azolo-oxindoles
09/23/2008CA2354039C Pharmaceutical formulations in hydroxypropylmethylcellulose capsules
09/23/2008CA2351727C Crystals of 5-[{6-(2-fluorobenzyl)oxy-2-naphthyl}methyl]-2,4-thiazolidinedione
09/23/2008CA2333323C Method and compositions for treatment of cancers
09/23/2008CA2305790C Styryl sulfone anticancer agents
09/23/2008CA2293373C Benzo(5,6)cyclohepta(1,2b)pyridine derivatives useful for inhibition of farnesyl protein transferase
09/23/2008CA2283643C Certain cyclic thio substituted acylaminoacid amide derivatives
09/23/2008CA2266479C Vitamin d analogues
09/23/2008CA2259940C High-affinity interleukin-4 muteins
09/23/2008CA2208484C Soluble 2-chloro-2'-deoxyadenosine formulations
09/23/2008CA2187283C Circularly permuted ligands and circularly permuted chimeric molecules
09/23/2008CA2186004C Isolated peptides derived from mage tumor rejection antigen precursors which complex with hla-a2 molecules
09/23/2008CA2163256C Adenoviral vectors of animal origin and use thereof in gene therapy
09/23/2008CA2118373C Method to reverse the phenotype of transformed cells by the transcription factor irf-1
09/21/2008CA2637157A1 Mesenchymal stem cells and uses therefor
09/18/2008WO2008112934A1 Intravesical apaziquone administration following transurethral resection for treating cancer
09/18/2008WO2008112509A1 Treatment of melanoma
09/18/2008WO2008112498A2 Synthesis and characterization of polymorph form ii of 4-(2-(4,4-dimethyl-2-oxooxazolidin-3-yl)thiazol-4-yl)benzonitrile
09/18/2008WO2008112495A1 Synthesis and characterization of polymorph form iii of 4-(2,(4,4-dimethyl-2-oxooxazolidin-3-yl)thiazol-4-yl)benzonitrile
09/18/2008WO2008112290A2 Use of ephb4 as a diagnostic marker and a therapeutic target for ovarian cancer
09/18/2008WO2008112199A1 Method for inhibiting topoisomerase ii
09/18/2008WO2008112192A2 Epha3 antibodies for the treatment of solid tumors
09/18/2008WO2008112141A1 Compositions for improving cellular uptake of a chemotherapeutic agent in a cell exhibiting mucin deregulation